Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Depression and Parkinson's disease.

Matthias R Lemke1, Gerd Fuchs, Irene Gemende

  • 1Rhine Clinic Bonn, Kaiser-Karl-Ring 20, 53111 Bonn, Germany. mr.lemke@lvr.de

Journal of Neurology
|January 29, 2005
PubMed
Summary

Depression significantly impacts Parkinson's disease (PD) patients, affecting quality of life. Effective treatments include certain antidepressants and dopamine agonists, though more research and better diagnostic tools are needed for this specific patient group.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cognitive structure and progression in Parkinson's disease: insights from a tablet-based assessment.

Scientific reports·2026
Same author

Fortschritte der Neurologie-Psychiatrie·2026
Same author

The German Parkinson expert meetings.

Journal of neural transmission (Vienna, Austria : 1996)·2026
Same author

Why dopamine replacement therapy will stay as a cornerstone in the treatment of Parkinson disease: a personal opinion.

Journal of neural transmission (Vienna, Austria : 1996)·2026
Same author

Amantadine-based combination therapy of Parkinson's disease to prevent fluctuation and dyskinesia - experiences from a Parkinson outpatient clinic.

Frontiers in aging neuroscience·2026
Same author

CSF alpha-Synuclein Seed Amplification Assay results in routine clinically collected samples.

Journal of Parkinson's disease·2026

Area of Science:

  • Neurology
  • Psychiatry
  • Pharmacology

Background:

  • Depression affects nearly half of Parkinson's disease (PD) patients, independent of motor symptoms.
  • PD-related depression symptoms differ from major depression, often presenting as anhedonia and emptiness.
  • Anxiety and depression can precede motor symptoms in PD by many years.

Purpose of the Study:

  • To review the characteristics, diagnosis, and treatment of depression in Parkinson's disease.
  • To highlight the limitations of current diagnostic tools for PD-related depression.
  • To discuss the role of neurotransmitter systems and pharmacological interventions in managing depression in PD.

Main Methods:

  • Literature review of studies on depression in Parkinson's disease.

Related Experiment Videos

  • Analysis of the etiological roles of serotonergic, noradrenergic, and dopaminergic mechanisms.
  • Evaluation of antidepressant efficacy, including SSRIs, SNRIs, and dopamine agonists.

    • Main Results:

    • Selective serotonin and noradrenaline reuptuptake inhibitors (SSRIs, SNRIs) show effectiveness with favorable side effect profiles.
    • Dopamine agonists like pramipexole and ropinirole demonstrate potential in ameliorating depressive symptoms in PD.
    • Current rating scales for major depression may not adequately assess depression severity in PD patients.

    Conclusions:

    • Depression is a significant, often undertreated, comorbidity in Parkinson's disease.
    • Pharmacological treatments, including SSRIs, SNRIs, and specific dopamine agonists, offer therapeutic benefits.
    • Further research is needed to develop appropriate rating scales and conduct controlled studies for depression in PD.